R

Roche

Global pharmaceuticals and diagnostics company

Global Diagnostics Partnering Lead (Senior Manager, Director) - Strategy & Transactions

Full-Time
No salary listed
Expert
Bachelor's, Master's, PhD
Suzhou, Jiangsu, China+1 moreMore locations: Shanghai, China
In PersonThe role requires working outside standard office hours to accommodate time zones.
Business & StrategyCorporate Strategy

About the job

Requirements
  • Hold an advanced degree in science, engineering, or a related field; a PhD or Master's is ideally preferred.
  • Have a solid understanding of the diagnostics industry, including lifecycle processes, development, and global business development trends.
  • Demonstrate experience or a background in business or corporate development, strategy consulting, venture capital, investment banking, or a related field; this is a strong plus rather than a strict requirement.
  • Bring broad knowledge and ideally a track record in negotiating business partnerships or transactions such as mergers and acquisitions, licensing, research and development, and commercial collaboration agreements.
  • Have knowledge of accounting, finance, and financial modeling.
  • Have a track record of managing multiple high-performing cross-functional teams and projects.
  • Demonstrate strategic thinking, analytical and conceptual problem-solving skills, and written and oral communication abilities to distill complex problems and proposals into clear, succinct decision documents for management and governance bodies.
  • Demonstrate planning and organizational skills, cross-functional collaboration, continuous learning, coaching and mentoring, ability to navigate organizational change, objectivity, fairness, open communication, consensus-building, and respect for differences of opinion.
  • Be fluent in Mandarin Chinese and English.
Responsibilities
  • Define external growth strategy by providing expertise and thought leadership within squad teams to proactively generate strategic opportunities that contribute to Roche Diagnostics' strategy.
  • Co-create strategic partnering wants and target product profiles with internal stakeholders in line with Roche Diagnostics' strategy.
  • Generate and secure a continuous flow of attractive partnership options by maintaining strong internal and external networks.
  • Proactively conduct systematic screening, in close collaboration with the Science and Technology Team and business stakeholders, for suitable technologies, products, digital solutions, and companies.
  • Evaluate and prioritize external partnership options against strategic wants and target product profiles, including strategic, financial, and feasibility assessments and selection of appropriate deal structures, with an emphasis on business modeling.
  • Lead preparation, structuring, and negotiation of new business partnership and transaction agreements, including licensing, research and development, and commercial collaboration agreements, in collaboration with squad members and internal stakeholders.
  • Work with Group Business Development as a team on mergers and acquisitions transactions.
  • Lead and provide best practices in planning and conducting due diligence on external partnership options against strategic wants or target product profiles.
  • Prepare objective, sound recommendations regarding specific business partnerships for senior management and governance bodies.
  • Establish business relationships and collaborate with Partnering Alliances & Ecosystem Management team members following execution of a partnership or transaction.
  • Lead matrix project teams driving Roche Diagnostics' external growth strategy globally and work outside standard office hours to accommodate time zones.
Desired Qualifications
  • Experience or a background in business or corporate development, strategy consulting, venture capital, investment banking, or a related field is a strong plus.
  • A PhD or Master's degree is ideally preferred.
  • A track record in negotiating business partnerships or transactions is ideally preferred.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus

Company News

Yahoo Finance
Oct 16th, 2026
FDA approves Roche's Enspryng as first at-home injection for thyroid eye disease

Roche said the US Food and Drug Administration (FDA) has approved Enspryng (satralizumab) for adults with thyroid eye disease (TED). It is the first and only at-home subcutaneous treatment for the condition, and a patient or caregiver can administer it after training. In the Phase III SatraGO-2 trial, 52.9% of active TED patients on Enspryng had a proptosis (eye bulging) response, against 23.4% on placebo. Double vision fell in 60.7% of patients, against 25.8%. The SatraGO-1 trial missed its primary endpoint at Week 24. No new safety signals emerged. TED affects about 155 in every 100,000 people in the US. This is Enspryng's second approval, after neuromyelitis optica spectrum disorder in 2020. The FDA is also reviewing it for myelin oligodendrocyte glycoprotein antibody-associated disease, with a decision expected in January 2027.

Yahoo Finance
Oct 9th, 2026
FDA approves Roche's Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The US Food and Drug Administration has approved Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth approved indication in the US. The approval follows the phase III ATOMIC study, published in The New England Journal of Medicine, which demonstrated that Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% with the combination versus 76% with chemotherapy alone. Nearly 25% of colon cancers are diagnosed at stage III, and almost one in three stage III patients experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population. Roche is pursuing further regulatory filings, including with the European Medicines Agency.

Yahoo Finance
Sep 30th, 2026
Roche's enicepatide shows 22.5% weight loss in 48 weeks, challenging Eli Lilly and Novo Nordisk

Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.

PR Newswire
Sep 30th, 2026
Roche launches newborn screening test for SMA, SCID and sickle cell disease

Roche has launched a newborn screening test that simultaneously detects three severe genetic conditions: Spinal Muscular Atrophy, Severe Combined Immunodeficiency Disease, and Sickle Cell Disease. TIB MOLBIOL, a Roche subsidiary, developed the LightMix Newborn TREC/SMN1/HBB kit for use in countries accepting the CE mark. The test enables early detection before symptoms appear, allowing clinicians to initiate life-changing treatments sooner. Early intervention can prevent severe nerve damage in SMA, enable lifesaving bone marrow transplants for SCID, and drastically lower infant mortality in SCD through preventive measures. The IVDR-approved test provides a ready-to-use solution that integrates into existing laboratory workflows. It runs on established LightCycler systems, making it accessible for private and academic hospital laboratories across Europe.

Yahoo Finance
Sep 13th, 2026
Roche's Tam-Peli cuts death risk by 54% in Chinese SCLC trial, global phase III studies planned

Roche's collaborator MediLink has announced positive phase III results for tambotatug pelitecan (Tam-Peli) in Chinese patients with relapsed small-cell lung cancer. The TAISHAN-302 trial showed Tam-Peli reduced the risk of death by 54% compared to topotecan, with median overall survival of 13.3 versus 9.4 months. The antibody-drug conjugate also demonstrated superior progression-free survival (7.4 versus 2.8 months) and objective response rates (59.1% versus 9.7%). China's National Medical Products Administration has accepted the New Drug Application for filing. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials. The therapy has received Breakthrough Therapy Designations from both the US FDA and China CDE for relapsed small-cell lung cancer.